Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 4,670 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Respiratory Therapy Clear all

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 85
States / cities: Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more

Conditions: Cancer of the Lung, Lung Cancer, Lung Neoplasms, Adenocarcinoma of the Lung, Non Small Cell Carcinoma of the Lung, Small Cell Carcinoma of the Lung
Interventions: Not listed
Lead sponsor: Pathway Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Acute Respiratory Distress Syndrome
Interventions: A.1 Lucinactant, B.3 SoC, A.2 Lucinactant, A.3 Lucinactant, A.4 Lucinactant, B.1 Lucinactant, B.2 Lucinactant; Drug · Other
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Warrington, Pennsylvania

Conditions: COVID-19, Corona Virus Infection, Coronavirus-19, Sars-CoV2
Interventions: Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, Zinc; Drug · Dietary Supplement
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ventura, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Tarzana, California • Torrance, California + 4 more

Conditions: Bronchiolitis Obliterans, Constructive Bronchiolitis, Graft Versus Host Disease, Bronchiolitis, Exudative, Bronchiolitis, Proliferative, Graft-Versus-Host Disease
Interventions: Cyclosporine Inhalation Solution (CIS); Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vaccination Refusal, COVID-19
Interventions: Short Message Service (SMS) + Website Link Strategy, Phone Call with Peer Strategy; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Not listed
Enrollment: 262 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Hazelwood, Missouri • Jennings, Missouri • Saint Ann, Missouri + 2 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Graft Versus Host Disease
Interventions: Tocilizumab; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Acute Respiratory Infection, Bronchitis, Rhinosinusitis
Interventions: Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets); Drug
Lead sponsor: Adams Respiratory Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 28
States / cities: Birmingham, Alabama • Carmichael, California • Torrance, California + 24 more

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: PT-523 for Injection; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Miami, Florida • Chicago, Illinois • Durham, North Carolina + 1 more

Conditions: Non-small Cell Lung Cancer, Oligoprogressive, Small-cell Lung Cancer
Interventions: Ablative local therapy; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Seasonal Allergic Rhinitis
Interventions: Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray, Placebo nasal spray; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 30
States / cities: Stockbridge, Georgia • Louisville, Kentucky • Baltimore, Maryland + 21 more

Conditions: Asthma
Interventions: Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 50
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 42 more

Conditions: Lung Cancer, Brain Cancer, Head and Neck Cancer
Interventions: Siemens Somatom Definition Edge, Philips Brilliance Big Bore CT/simulator; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Asthma
Interventions: Brenipatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 17
States / cities: Tempe, Arizona • Newport Beach, California • Northridge, California + 13 more

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: Vorolanib, Atezolizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pneumonia
Interventions: Cethromycin, Clarithromycin; Drug
Lead sponsor: Advanced Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: Woodridge, Illinois

Conditions: Asthma
Interventions: Pictorial asthma action plan, Written asthma action plan; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 6 Years to 18 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Lung Cancer Patients, Caregivers
Interventions: There are no interventions in this study. All participants complete online surveys.; Other
Lead sponsor: LUNGevity Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Interventions: Viewray MRIdian® Linac; Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Obstructive Sleep Apnea
Interventions: Eszopiclone 2 mg, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chronic Bronchitis
Interventions: Faropenem medoxomil, placebo; Drug
Lead sponsor: Replidyne; Industry
Eligibility: 35 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New Hope, Pennsylvania

Conditions: COVID-19
Interventions: Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™, Placebo; Drug
Lead sponsor: Jose David Suarez, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

KL₄Surfactant Treatment in Patients With ARDS

A Study of Quintuple Therapy to Treat COVID-19 Infection

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans

COVID-19 Vaccine Uptake Trial

RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

Phase 4 Study - Mucinex D as Adjunct Therapy

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of Patients Treated With Proton or Photon Therapy

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)

Comparing Asthma Action Plans for Pediatric Asthma

Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)

A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis

LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19